For the past 12 years Dr. Saag has been devoting the majority of his career efforts to patient-oriented research in the pharmacoepidemiology of the rheumatic diseases. In addition to competing successfully for peer reviewed grants, including a recent renewal of his $3.2 million AHRQ supported Center for Education and Research on Therapeutics (CERTs) of musculoskeletal disorders, Dr. Saag has published or has in press 50 original reports. Since joining the UAB faculty in 1998, Dr. Saag has been a primary or secondary mentor for rheumatology fellows (2), international fellows (3), and junior faculty members (5), several of whom have already received career development awards. As a clinical investigator, Dr. Saag balances research with patient care and teaching responsibilities. Receipt of a K24 grant would assure his protected time at 50% or greater effort and relieve future clinical and administrative responsibilities. It will increase his time for mentoring and he will add additional trainees and assume new mentoring responsibilities. It is anticipated that one or two new trainees will be recruited into Dr. Saag's research program each year. He will lead a new Arthritis Outcomes and Epidemiology Seminar Series and expand his mentoring role in other areas such as the VA Quality Scholars Program. Following existing UAB models, a program for formal mentoring feedback will be established to guide and refine his mentoring activities. UAB has extensive infrastructure including several T32 training grants, a K30, and numerous pre-existing programs that will facilitate Dr. Saag's training of patient oriented researchers. Thus, UAB and its Schools, Departments, Divisions, and Interdisciplinary Centers provide an outstanding environment for the development of junior investigators in patient-oriented research. Based on institutional commitment and resources and Dr. Saag's successful past record in research and mentoring, the K24 will greatly enhance his ability to expand his research program and to help develop the next generation of patient-oriented clinical investigators.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24AR052361-04
Application #
7436107
Study Section
Special Emphasis Panel (ZAR1-GHZ-D (J1))
Program Officer
Witter, James
Project Start
2005-06-01
Project End
2010-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
4
Fiscal Year
2008
Total Cost
$146,233
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Wolinsky, F D; Lou, Y; Edmonds, S W et al. (2017) The effects of a patient activation intervention on smoking and excessive drinking cessations: results from the PAADRN randomized controlled trial. Osteoporos Int 28:3055-3060
Wolinsky, F D; Hall, S F; Lou, Y et al. (2017) The cost of a patient activation intervention for achieving successful outcomes: results from the PAADRN randomized controlled trial. Osteoporos Int 28:3061-3066
Wolinsky, Fredric D; Lou, Yiyue; Edmonds, Stephanie W et al. (2017) Activating Patients With a Tailored Bone Density Test Results Letter and Educational Brochure: the PAADRN Randomized Controlled Trial. J Clin Densitom 20:464-471
Cram, Peter; Saag, Kenneth G; Lou, Yiyue et al. (2017) Racial Differences and Disparities in Osteoporosis-related Bone Health: Results From the PAADRN Randomized Controlled Trial. Med Care 55:561-568
Nguyen, V T; Edmonds, S W; Lou, Y et al. (2017) Validity, reliability, and responsiveness to change of the ""Osteoporosis and You"" knowledge scale. Osteoporos Int 28:3379-3388
Roblin, Douglas W; Zelman, David; Plummer, Sally et al. (2017) Evaluation of a ""Just-in-Time"" Nurse Consultation on Bone Health: A Pilot Randomized Controlled Trial. Perm J 21:
Hall, Sylvie F; Edmonds, Stephanie W; Lou, Yiyue et al. (2017) Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. J Am Pharm Assoc (2003) 57:503-509
Cram, P; Wolinsky, F D; Lou, Y et al. (2016) Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial. Osteoporos Int 27:3513-3524
Saddekni, Michael B; Saag, Kenneth G; Dudenbostel, Tanja et al. (2016) The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale. Contemp Clin Trials 50:238-44
Danila, Maria I; Outman, Ryan C; Rahn, Elizabeth J et al. (2016) A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material. Contemp Clin Trials Commun 4:14-24

Showing the most recent 10 out of 57 publications